|
1
|
Feu F, García-Pagín JC, Bosch J, Luca A,
Terés J, Escorsell A and Rodés J: Relation between portal pressure
response to pharmacotherapy and risk of recurrent variceal
haemorrhage in patients with cirrhosis. Lancet. 346:1056–1059.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Groszmann RJ, Bosch J, Grace ND, Conn HO,
Garcia-Tsao G, Navasa M, Alberts J, Rodes J, Fischer R, Bermann M,
et al: Haemodynamic events in a prospective randomized trial of
propranolol versus placebo in the prevention of a first variceal
hemorrhage. Gastroenterology. 99:1401–1407. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Garcia-Tsao G and Bosch J: Management of
varices and variceal hemorrhage in cirrhosis. N Engl J Med.
362:823–832. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bataller R, Ginès P, Nicolás JM, Görbig
MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V and Rodés J:
Angiotensin II induces contraction and proliferation of human
hepatic stellate cells. Gastroenterology. 118:1149–1156. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garcia-Pagán JC, Salmerón JM, Feu F, Luca
A, Ginés P, Pizcueta P, Claria J, Piera C, Arroyo V, Bosch J, et
al: Effects of low-sodium diet and spironolactone on portal
pressure in patients with compensated cirrhosis. Hepatology.
19:1095–1099. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sowers JR, Whaley-Connell A and Epstein M:
Narrative review: The emerging clinical implications of the role of
aldosterone in the metabolic syndrome and resistant hypertension.
Ann Intern Med. 150:776–783. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tandon P, Abraldes JG, Berzigotti A,
Garcia-Pagan JC and Bosch J: Renin-angiotensin-aldosterone
inhibitors in the reduction of portal pressure: A systematic review
and meta-analysis. J Hepatol. 53:273–282. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De BK, Dutta D, Som R, Biswas PK, Pal SK
and Biswas A: Haemodynamic effects of propranolol with
spironolactone in patients with variceal bleeds: A randomized
controlled trial. World J Gastroenterol. 14:1908–1913. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schepke M, Wiest R, Flacke S, Heller J,
Stoffel-Wagner B, Herold T, Ghauri M and Sauerbruch T: Irbesartan
plus low-dose propranolol versus low-dose propranolol alone in
cirrhosis: A placebo-controlled, double-blind study. Am J
Gastroenterol. 103:1152–1158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abecasis R, Kravetz D, Fassio E,
Ameigeiras B, Garcia D, Isla R, Landeira G, Dominguez N, Romero G,
Argonz J and Terg R: Nadolol plus spironolactone in the prophylaxis
of first variceal bleed in nonascitic cirrhotic patients: A
preliminary study. Hepatology. 37:359–365. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H, Yang J, Zhu R, Zheng Y, Zhou Y,
Dai W, Wang F, Chen K, Li J, Wang C, et al: Combination therapy of
ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: A
meta-analysis. Drug Des Devel Ther. 9:567–574. 2015.PubMed/NCBI
|
|
12
|
Zhang Y, Li S, He L, Wang F, Chen K, Li J,
Liu T, Zheng Y, Wang J, Lu W, et al: Combination therapy of
fenofibrate and ursodeoxycholic acid in patients with primary
biliary cirrhosis who respond incompletely to UDCA monotherapy: A
meta-analysis. Drug Des Devel Ther. 9:2757–2766. 2015.PubMed/NCBI
|
|
13
|
Kjaergard LL, Villumsen J and Gluud C:
Reported methodologic quality and discrepancies between large and
small randomized trials in meta-analyses. Ann Intern Med.
135:982–989. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gluud LL: Bias in clinical intervention
research. Am J Epidemiol. 163:493–501. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sen S, De BK, Biswas PK, Biswas J, Das D
and Maity AK: Haemodynamic effect of spironolactone in liver
cirrhosis and propranolol-resistant portal hypertension. Indian J
Gastroenterol. 21:145–148. 2002.PubMed/NCBI
|
|
17
|
Winkler C, Hobolth L, Krag A, Bendtsen F
and Møller S: Effects of treatment with β-blocker and aldosterone
antagonist on central and peripheral haemodynamics and oxygenation
in cirrhosis. Eur J Gastroenterol Hepatol. 23:334–342. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
De BK, Bandyopadhyay K, Das TK, Das D,
Biswas PK, Majumdar D, Mandal SK, Ray S and Dasgupta S: Portal
pressure response to losartan compared with propranolol in patients
with cirrhosis. Am J Gastroenterol. 98:1371–1376. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Castano G, Viudez P, Riccitelli M and
Sookoian S: A randomized study of losartan vs propranolol: Effects
on hepatic and systemic haemodynamics in cirrhotic patients. Ann
Hepatol. 2:36–40. 2003.PubMed/NCBI
|
|
20
|
Agasti AK, Mahajan AU, Phadke AY, Nathani
PJ and Sawant P: Comparative randomized study on efficacy of
losartan versus propranolol in lowering portal pressure in
decompensated chronic liver disease. J Dig Dis. 14:266–271. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Debernardi-Venon W, Martini S, Biasi F,
Vizio B, Termine A, Poli G, Brunello F, Alessandria C, Bonardi R,
Saracco G, et al: AT1 receptor antagonist Candesartan in selected
cirrhotic patients: Effect on portal pressure and liver fibrosis
markers. J Hepatol. 46:1026–1033. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gonzalez-Abraldes J, Albillos A, Bañares
R, Del Arbol LR, Moitinho E, Rodríguez C, González M, Escorsell A,
García-Pagán JC and Bosch J: Randomized comparison of long-term
losartan versus propranolol in lowering portal pressure in
cirrhosis. Gastroenterology. 121:382–388. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Venon WD, Baronio M, Leone N, Rolfo E,
Fadda M, Barletti C, Todros L, Saracco G and Rizzetto M: Effects of
long-term Irbesartan in reducing portal pressure in cirrhotic
patients: Comparison with propranolol in a randomised controlled
study. J Hepatol. 38:455–460. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nevens F, Lijnen P, VanBilloen H and
Fevery J: The effect of long-term treatment with spironolactone on
variceal pressure in patients with portal hypertension without
ascites. Hepatology. 23:1047–1052. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vilas-Boas WW, Ribeiro-Oliveira A Jr, Rda
Ribeiro C, Vieira RL, Almeida J, Nadu AP, Simões e Silva AC and
Santos RA: Effect of propranolol on the splanchnic and peripheral
renin angiotensin system in cirrhotic patients. World J
Gastroenterol. 14:6824–6830. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pagliaro L: Lebrec D, Poynard T, Hillon P,
Benhamou J-P. Propranolol for prevention of recurrent
gastrointestinal bleeding in patients with cirrhosis. A controlled
study [N Engl J Med 1981;305:1371-1374]. J Hepatol. 36:148–150.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shah HA, Azam Z, Rauf J, Abid S, Hamid S,
Jafri W, Khalid A, Ismail FW, Parkash O, Subhan A and Munir SM:
Carvedilol vs. esophageal variceal band ligation in the primary
prophylaxis of variceal hemorrhage: A multicentre randomized
controlled trial. J Hepatol. 60:757–764. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lazebnik LB, Mikheeva OM, Toporkov AS,
Komissarenko IA, Vasnev OS and Fedulenkova LV: Correction of portal
hypertension by beta-adrenoblockers (atenolol and metoprolol) and
inhibitors of ACE (lisinopril and enalapril) in liver cirrhosis.
Eksp Klin Gastroenterol. 57–66. 2007.PubMed/NCBI
|
|
29
|
Wagatsuma Y, Naritaka Y, Shimakawa T,
Kanako H, Keiichiro I, Shunichi S, Konno S, Katsube T and Ogawa K:
Clinical usefulness of the angiotensin II receptor antagonist
losartan in patients with portal hypertensive gastropathy.
Hepatogastroenterology. 53:171–174. 2006.PubMed/NCBI
|
|
30
|
Baik SK, Park DH, Kim MY, Choi YJ, Kim HS,
Lee DK, Kwon SO, Kim YJ, Park JW and Chang SJ: Captopril reduces
portal pressure effectively in portal hypertensive patients with
low portal venous velocity. J Gastroenterol. 38:1150–1154. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Klein CG: Medicinal influence on portal
vein haemodynamics by cirrhosis of the liver-comparison between
angiotensin II receptor antagonists and β-blockers in combination
with spironolactone. J Zeitschrift fur Gastroenterologie.
39:6692001.
|
|
32
|
Alessandria C, Elia C, Mezzabotta L, Risso
A, Andrealli A, Spandre M, Morgando A, Marzano A and Rizzetto M:
Prevention of paracentesis-induced circulatory dysfunction in
cirrhosis: Standard vs half albumin doses. A prospective,
randomized, unblinded pilot study. Dig Liver Dis. 43:881–886.
2011.PubMed/NCBI
|
|
33
|
Block JP: Rifaximin improves the treatment
of hepatic encephalopathy. J Clin Outcomes Manage. 17:202–204.
2010.
|
|
34
|
Bass NM, Mullen KD, Sanyal A, Poordad F,
Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, et
al: Rifaximin treatment in hepatic encephalopathy. N Engl J Med.
362:1071–1081. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Van den Velde S, Nevens F, Van hee P, van
Steenberghe D and Quirynen M: GC-MS analysis of breath odor
compounds in liver patients. J Chromatogr B Analyt Technol Biomed
Life Sci. 875:344–348. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hsien L, Breddemann A, Frobel AK, Heusch
A, Schmidt KG and Läer S: Off-label drug use among hospitalised
children: Identifying areas with the highest need for research.
Pharm World Sci. 30:497–502. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Revill P, Serradell N, Bolós J and Bayes
M: Satavaptan. Drug Fut. 32:26–36. 2007. View Article : Google Scholar
|
|
38
|
Merkel C: Nonselective beta-blockers plus
nitrates in portal hypertension: An open question. Hepatology.
37:1254–1256. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Merkel C, Sacerdoti D, Bolognesi M, et al:
Pharmacological associations in the primary/prophylaxis of variceal
bleeding in cirrhosis. Giornale Italiano di Endoscopia Digestiva.
21:1–5. 1998.
|
|
40
|
Fox K, Ford I, Steg PG, Tardif JC, Tendera
M and Ferrari R: SIGNIFY Investigators: Ivabradine in stable
coronary artery disease without clinical heart failure. N Engl J
Med. 371:1091–1099. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rupnik Trošt A, Pajek J, Guček A, Osredkar
J, Kovač D, Bren A, Klančič D, Saksida S, Rus I, Globokar M, et al:
Influence of renin-angiotensin-aldosterone system-blocking drugs on
peritoneal membrane in peritoneal dialysis patients. Ther Apher
Dial. 17:425–430. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fallahzadeh MK, Dormanesh B, Sagheb MM,
Roozbeh J, Vessal G, Pakfetrat M, Daneshbod Y, Kamali-Sarvestani E
and Lankarani KB: Effect of addition of silymarin to
renin-angiotensin system inhibitors on proteinuria in type 2
diabetic patients with overt nephropathy: A randomized,
double-blind, placebo-controlled trial. Am J Kidney Dis.
60:896–903. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kosmala W, Przewlocka-Kosmala M,
Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T and Marwick TH:
A randomized study of the beneficial effects of aldosterone
antagonism on LV function, structure, and fibrosis markers in
metabolic syndrome. JACC Cardiovasc Imaging. 4:1239–1249. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Spinar J, Vitovec J and Spinarová L:
Zastoupení resitelů studie FARIM: FARIM-FARmakoterapie po Infarktu
Myokardu (Post-Myocardial Infarction Pharmacotherapy Study).
Vnitrni lekarstvi. 57:778–784. 2011.(In Czech). PubMed/NCBI
|
|
45
|
Guney I, Selcuk NY, Altintepe L, Atalay H,
Başarali MK and Büyükbaş S: Antifibrotic effects of aldosterone
receptor blocker (spironolactone) in patients with chronic kidney
disease. Ren Fail. 31:779–784. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tylicki L, Renke M, Rutkowski P,
Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W and Rutkowski
B: Dual blockade of the renin-angiotensin-aldosterone system with
high-dose angiotensin-converting enzyme inhibitor for
nephroprotection: An open, controlled, randomized study. Scand J
Urol Nephrol. 42:381–388. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tylicki L, Rutkowski P, Renke M,
Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W and Rutkowski
B: Triple pharmacological blockade of the
renin-angiotensin-aldosterone system in nondiabetic CKD: An
open-label crossover randomized controlled trial. Am J Kidney Dis.
52:486–493. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Muller-Brunotte R, Kahan T, López B, Edner
M, González A, Díez J and Malmqvist K: Myocardial fibrosis and
diastolic dysfunction in patients with hypertension: Results from
the Swedish Irbesartan Left Ventricular Hypertrophy Investigation
versus Atenolol (SILVHIA). J Hypertens. 25:1958–1966. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Orea-Tejeda A, Colín-Ramírez E,
Castillo-Martínez L, Asensio-Lafuente E, Corzo-León D,
González-Toledo R, Rebollar-González V, Narváez-David R and
Dorantes-García J: Aldosterone receptor antagonists induce
favorable cardiac remodeling in diastolic heart failure patients.
Rev Invest Clin. 59:103–107. 2007.PubMed/NCBI
|
|
50
|
Cavallari LH, Momary KM, Groo VL, Viana
MA, Camp JR and Stamos TD: Association of beta-blocker dose with
serum procollagen concentrations and cardiac response to
spironolactone in patients with heart failure. Pharmacotherapy.
27:801–812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tylicki L, Biedunkiewicz B, Chamienia A,
Wojnarowski K, Zdrojewski Z, Aleksandrowicz E, Lysiak-Szydlowska W
and Rutkowski B: Renal allograft protection with angiotensin II
type 1 receptor antagonists. Am J Transplant. 7:243–248. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Christensen MK, Olsen MH, Wachtell K,
Tuxen C, Fossum E, Bang LE, Wiinberg N, Devereux RB, Kjeldsen SE,
Hildebrandt P, et al: Does long-term losartan- vs atenolol-based
antihypertensive treatment influence collagen markers differently
in hypertensive patients? A LIFE substudy. Blood Press. 15:198–206.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ciulla MM, Paliotti R, Esposito A, Dìez J,
López B, Dahlöf B, Nicholls MG, Smith RD, Gilles L, Magrini F and
Zanchetti A: Different effects of antihypertensive therapies based
on losartan or atenolol on ultrasound and biochemical markers of
myocardial fibrosis: Results of a randomized trial. Circulation.
110:552–557. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hallberg P, Lind L, Billberger K,
Michaelsson K, Karlsson J, Kurland L, Kahan T, Malmqvist K, Ohman
KP, Nyström F, et al: Transforming growth factor beta1 genotype and
change in left ventricular mass during antihypertensive
treatment-results from the Swedish Irbesartan Left Ventricular
Hypertrophy Investigation versus Atenolol (SILVHIA). Clin Cardiol.
27:169–173. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
el-Agroudy AE, Hassan NA, Foda MA, Ismail
AM, el-Sawy EA, Mousa O and Ghoneim MA: Effect of angiotensin II
receptor blocker on plasma levels of TGF-beta 1 and interstitial
fibrosis in hypertensive kidney transplant patients. Am J Nephrol.
23:300–306. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hayashi M, Tsutamoto T, Wada A, Tsutsui T,
Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, et al:
Immediate administration of mineralocorticoid receptor antagonist
spironolactone prevents post-infarct left ventricular remodeling
associated with suppression of a marker of myocardial collagen
synthesis in patients with first anterior acute myocardial
infarction. Circulation. 107:2559–2565. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yang YY, Lin HC, Lee WP, Chu CJ, Lin MW,
Lee FY, Hou MC, Jap JS and Lee SD: Association of the G-protein and
α2-adrenergic receptor gene and plasma norepinephrine level with
clonidine improvement of the effects of diuretics in patients with
cirrhosis with refractory ascites: A randomised clinical trial.
Gut. 59:1545–1553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ljubicić N, Bilić A and Plavsić V: Effect
of propranolol on urinary prostaglandin E2 excretion and renal
interlobar arterial blood flow after furosemide administration in
patients with hepatic cirrhosis. Eur J Clin Pharmacol. 43:555–558.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mikheeva OM, Drozdov VN and Komisarenko
IA: Pharmacokinetic and pharmacodynamic characteristics of
antihypertensive drugs in the treatment of hypertensive patients
with chronic diseases of the liver. Ter Arkh. 83:49–55.
2011.PubMed/NCBI
|
|
60
|
Mikheeva OM: Pharmacokinetic and
pharmacodynamic features of hypertensive drugs in treatment of
patients with arterial hypertension associated with liver disease.
Eksp Klin Gastroenterol. 95–101. 2010.(In Russian). PubMed/NCBI
|
|
61
|
Nevens F: Non-invasive variceal pressure
measurements: Validation and clinical implications. Verh K Acad
Geneeskd Belg. 58:413–437. 1996.PubMed/NCBI
|
|
62
|
Talwalkar JA and Kamath PS: Influence of
recent advances in medical management on clinical outcomes of
cirrhosis. Mayo Clin Proc. 80:1501–1508. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yang JD and Kim WR: Surveillance for
hepatocellular carcinoma in patients with cirrhosis. Clin
Gastroenterol Hepatol. 10:16–21. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lubel JS, Herath CB, Burrell LM and Angus
PW: Liver disease and the renin-angiotensin system: Recent
discoveries and clinical implications. J Gastroenterol Hepatol.
23:1327–1338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Albillos A: Preventing first variceal
hemorrhage in cirrhosis. J Clin Gastroenterol. 41:(Suppl 3).
S305–S311. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Garcia-Tsao G, Sanyal AJ, Grace ND and
Carey W: Practice Guidelines Committee of the American Association
for the Study of Liver Diseases; Practice Parameters Committee of
the American College of Gastroenterology: Prevention and management
of gastroesophageal varices and variceal hemorrhage in cirrhosis.
Hepatology. 46:922–938. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Samonakis DN, Triantos CK, Thalheimer U,
Patch DW and Burroughs AK: Management of portal hypertension.
Postgrad Med J. 80:634–641. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
D'Amico G: The role of vasoactive drugs in
the treatment of oesophageal varices. Expert Opin Pharmacother.
5:349–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Rosado B and Kamath PS: Transjugular
intrahepatic portosystemic shunts: An update. Liver Transpl.
9:207–217. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Bosch J: The sixth Carlos E. Rubio
memorial lecture. Prevention and treatment of variceal hemorrhage.
P R Health Sci J. 19:57–67. 2000.PubMed/NCBI
|
|
71
|
Patch D and Burroughs AK: Pharmacological
treatment of portal hypertension. Prog Liver Dis. 13:269–292.
1995.PubMed/NCBI
|
|
72
|
D'Amico G, Pagliaro L and Bosch J: The
treatment of portal hypertension: A meta-analytic review.
Hepatology. 22:332–354. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Forns X, Ginès A, Ginès P and Arroyo V:
Management of ascites and renal failure in cirrhosis. Semin Liver
Dis. 14:82–96. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Iwakiri Y: Pathophysiology of portal
hypertension. Clin Liver Dis. 18:281–291. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ohnishi K, Nakayama T, Saito M, Hatano H,
Tsukamoto T, Terabayashi H, Sugita S, Wada K, Nomura F, Koen H, et
al: Effects of propranolol on portal haemodynamics in patients with
chronic liver disease. Am J Gastroenterol. 80:132–135.
1985.PubMed/NCBI
|
|
76
|
Mastai R, Bosch J, Navasa M, Kravetz D,
Bruix J, Viola C and Rodés J: Effects of alpha-adrenergic
stimulation and beta-adrenergic blockade on azygos blood flow and
splanchnic haemodynamics in patients with cirrhosis. J Hepatol.
4:71–79. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Yoshiji H, Kuriyama S, Yoshii J, Ikenaka
Y, Noguchi R, Nakatani T, Tsujinoue H and Fukui H: Angiotensin-II
type 1 receptor interaction is a major regulator for liver fibrosis
development in rats. Hepatology. 34:745–750. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Schepke M, Werner E, Biecker E,
Schiedermaier P, Heller J, Neef M, Stoffel-Wagner B, Hofer U,
Caselmann WH and Sauerbruch T: Haemodynamic effects of the
angiotensin II receptor antagonist irbesartan in patients with
cirrhosis and portal hypertension. Gastroenterology. 121:389–395.
2001. View Article : Google Scholar : PubMed/NCBI
|
